6/11/2021 7:35:35 AM
Adamis Says Clinical Trial Start-up Activities Are Underway For Examining Effects Of Tempol
6/1/2021 7:42:54 AM
Adamis Provides Business Update; Says NDA For ZIMHI Submitted To FDA
5/17/2021 7:35:47 AM
Adamis Resubmits ZIMHI NDA To FDA For Treatment Of Opioid Overdose
4/12/2021 7:26:11 AM
Adamis Plans To Resubmit NDA For ZIMHI To FDA Within Next 45 Days
1/29/2021 9:10:06 AM
Adamis Prices Public Offering Of 40.54 Mln Shares Of Common Stock At $1.11/Shr
1/20/2021 9:01:33 AM
Adamis Announces IND Submission To FDA For Tempol For Treatment Of COVID-19
12/1/2020 9:17:43 AM
Adamis Intends To Address All Deficiencies Raised In ZIMHI CRL And Request FDA Approve NDA